Literature DB >> 11753385

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

Danilo Perrotti1, Vincenzo Cesi, Rossana Trotta, Clara Guerzoni, Giorgia Santilli, Kenneth Campbell, Angela Iervolino, Fabrizio Condorelli, Carlo Gambacorti-Passerini, Michael A Caligiuri, Bruno Calabretta.   

Abstract

The arrest of differentiation is a feature of both chronic myelogenous leukemia cells in myeloid blast crisis and myeloid precursors that ectopically express the p210BCR-ABL oncoprotein; however, its underlying mechanisms remain poorly understood. Here we show that expression of BCR-ABL in myeloid precursor cells leads to transcriptional suppression of the granulocyte colony-stimulating factor receptor G-CSF-R (encoded by CSF3R), possibly through down-modulation of C/EBPalpha-the principal regulator of granulocytic differentiation. Expression of C/EBPalpha protein is barely detectable in primary marrow cells taken from individuals affected with chronic myeloid leukemia in blast crisis. In contrast, CEBPA RNA is clearly present. Ectopic expression of C/EBPalpha induces granulocytic differentiation of myeloid precursor cells expressing BCR-ABL. Expression of C/EBPalpha is suppressed at the translational level by interaction of the poly(rC)-binding protein hnRNP E2 with CEBPA mRNA, and ectopic expression of hnRNP E2 in myeloid precursor cells down-regulates both C/EBPalpha and G-CSF-R and leads to rapid cell death on treatment with G-CSF (encoded by CSF3). Our results indicate that BCR-ABL regulates the expression of C/EBPalpha by inducing hnRNP E2-which inhibits the translation of CEBPA mRNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753385     DOI: 10.1038/ng791

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  110 in total

1.  Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells.

Authors:  Maria Rosa Lidonnici; Alessandra Audia; Angela Rachele Soliera; Marco Prisco; Giovanna Ferrari-Amorotti; Todd Waldron; Nick Donato; Ying Zhang; Robert V Martinez; Tessa L Holyoake; Bruno Calabretta
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.

Authors:  Arthur R Salomon; Scott B Ficarro; Laurence M Brill; Achim Brinker; Qui T Phung; Christer Ericson; Karsten Sauer; Ansgar Brock; David M Horn; Peter G Schultz; Eric C Peters
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-09       Impact factor: 11.205

3.  A novel set of nuclear localization signals determine distributions of the alphaCP RNA-binding proteins.

Authors:  Alexander N Chkheidze; Stephen A Liebhaber
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

4.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Authors:  Paolo Neviani; Jason G Harb; Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Justin J Ellis; Gregory Ferenchak; Adrienne M Dorrance; Carolyn A Paisie; Anna M Eiring; Yihui Ma; Hsiaoyin C Mao; Bin Zhang; Mark Wunderlich; Philippa C May; Chaode Sun; Sahar A Saddoughi; Jacek Bielawski; William Blum; Rebecca B Klisovic; Janelle A Solt; John C Byrd; Stefano Volinia; Jorge Cortes; Claudia S Huettner; Steffen Koschmieder; Tessa L Holyoake; Steven Devine; Michael A Caligiuri; Carlo M Croce; Ramiro Garzon; Besim Ogretmen; Ralph B Arlinghaus; Ching-Shih Chen; Robert Bittman; Peter Hokland; Denis-Claude Roy; Dragana Milojkovic; Jane Apperley; John M Goldman; Alistair Reid; James C Mulloy; Ravi Bhatia; Guido Marcucci; Danilo Perrotti
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 5.  C/EBPα deregulation as a paradigm for leukemogenesis.

Authors:  J A Pulikkan; D G Tenen; G Behre
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

6.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 8.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

9.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

10.  Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins.

Authors:  Lubov T Timchenko; Polina Iakova; Alana L Welm; Z-J Cai; Nikolai A Timchenko
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.